Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Controlled Company (unchanged) — Scilex Holding Company controls over 80% of voting power, giving it control over all stockholder votes including director elections and major corporate decisions.
  • Going Concern (unchanged) — Substantial doubt persists given cash of only $0.1M and operating cash outflow of $2.3M against minimal liquidity; the reported $154.3M net loss is overwhelmingly non-cash (Business Combination charges), not cash burn.
  • Material Weakness (unchanged) — Material weaknesses identified in internal control over financial reporting related to carve-out financial statement preparation and stock-based compensation expense.
  • Cryptocurrency Treasury Strategy (unchanged) — Filing maintains a standing Risks Related to Cryptocurrency disclosure for a named Bitcoin treasury/financing strategy that has not been implemented or tested (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material even when a related financing line moves out of Recent Developments.
OTC: SMNR Semnur Pharmaceuticals, Inc. 424B3

Semnur Pharmaceuticals registers 203.7M resale shares and 7.4M warrant shares; last sale $3.00

Filed June 15, 2026 · ~1 min read

Key Changes

  • high

    The prospectus registers up to 203,737,349 shares for resale by selling stockholders; the company receives no proceeds from these secondary sales.

    The Offering view on EDGAR →
  • medium

    Up to 7,432,122 shares may be issued upon exercise of warrants; the company would receive proceeds from warrant exercises.

    The Offering view on EDGAR →
  • medium

    The last reported sale price of common stock was $3.00 per share on June 15, 2026.

    The Offering view on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.

Partner

Trade SMNR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify